| (19) |
 |
|
(11) |
EP 2 628 486 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
30.10.2013 Bulletin 2013/44 |
| (43) |
Date of publication A2: |
|
21.08.2013 Bulletin 2013/34 |
| (22) |
Date of filing: 15.12.2008 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL
PT RO SE SI SK TR |
| (30) |
Priority: |
14.12.2007 US 13917 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
08863303.7 / 2227256 |
| (71) |
Applicant: AMGEN, INC. |
|
Thousand Oaks, CA 91320 (US) |
|
| (72) |
Inventor: |
|
- Ke, Hua, Zhu
CA, 91320 (US)
|
| (74) |
Representative: Power, David |
|
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB) |
|
| |
|
| (54) |
Method for treating bone fracture with anti-sclerostin antibodies |
(57) The invention is concerned with a sclerostin binding agent for use in a method for
treating a bone fracture in a subject, where the agent is administered to the subject
in a therapeutically effective amount from about 0.5 mg/kg to about 10 mg/kg, wherein
one or more administrations of the sclerostin binding agent are administered over
a treatment period lasting at least two weeks.